[{"orgOrder":0,"company":"University of New Hampshire","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"U.S.A","productType":"Small molecule","year":"2021","type":"Not Applicable","leadProduct":"JQ-1","moa":"BET","graph1":"Oncology","graph2":"Undisclosed","graph3":"University of New Hampshire","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"University of New Hampshire \/ Not Applicable","highestDevelopmentStatusID":"1","companyTruncated":"University of New Hampshire \/ Not Applicable"}]

Find Clinical Drug Pipeline Developments & Deals for JQ 1

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          University of New Hampshire

                          Country arrow
                          Antibody Engineering
                          Not Confirmed

                          University of New Hampshire

                          Country arrow
                          Antibody Engineering
                          Not Confirmed

                          Details : Researchers at the University found that adding venetoclax or panabinostat to the inhibitors was more effective than adding ibrutinib—with panobinostat offering the greatest combination therapy.

                          Brand Name : JQ-1

                          Molecule Type : Small molecule

                          Upfront Cash : Not Applicable

                          January 14, 2021

                          Lead Product(s) : JQ-1,Molibresib,Venetoclax

                          Therapeutic Area : Oncology

                          Highest Development Status : Undisclosed

                          Sponsor : Not Applicable

                          Deal Size : Not Applicable

                          Deal Type : Not Applicable

                          blank